Cross-Sector entity
Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Millennium Management LLC appears in 3 tracked Cross-Sector stories from August 9, 2026.
3 verified stories tracked
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Millennium Management LLC appears in 3 tracked Cross-Sector stories from August 9, 2026. The tracked stories average 2 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Millennium Management LLC. Shared-story counts are live from our verified record — not editorial picks.
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
